A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL

The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CASTEGINI, FRANCO, FAIELLA, GIANLUIGI, CAPONETTI, GIOVANNI, MAGGI, LORETTA, SARDINA, MARCO, REBOLINI, DANIELA
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CASTEGINI, FRANCO
FAIELLA, GIANLUIGI
CAPONETTI, GIOVANNI
MAGGI, LORETTA
SARDINA, MARCO
REBOLINI, DANIELA
description The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2983646A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2983646A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2983646A13</originalsourceid><addsrcrecordid>eNrjZHB0VAjwcAzydXR2DQ3xdHb0UXD29w3wD_YM8fT3A7L9Qhw9_Tz93BWcQl1cg_39PF1cFRz9XBTc_IN8_UNcg_x9eBhY0xJzilN5oTQ3g4Kba4izh25qQX58anFBYnJqXmpJvGuAkaWFsZmJmaOhMRFKAJ55Ktw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL</title><source>esp@cenet</source><creator>CASTEGINI, FRANCO ; FAIELLA, GIANLUIGI ; CAPONETTI, GIOVANNI ; MAGGI, LORETTA ; SARDINA, MARCO ; REBOLINI, DANIELA</creator><creatorcontrib>CASTEGINI, FRANCO ; FAIELLA, GIANLUIGI ; CAPONETTI, GIOVANNI ; MAGGI, LORETTA ; SARDINA, MARCO ; REBOLINI, DANIELA</creatorcontrib><description>The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160217&amp;DB=EPODOC&amp;CC=EP&amp;NR=2983646A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20160217&amp;DB=EPODOC&amp;CC=EP&amp;NR=2983646A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CASTEGINI, FRANCO</creatorcontrib><creatorcontrib>FAIELLA, GIANLUIGI</creatorcontrib><creatorcontrib>CAPONETTI, GIOVANNI</creatorcontrib><creatorcontrib>MAGGI, LORETTA</creatorcontrib><creatorcontrib>SARDINA, MARCO</creatorcontrib><creatorcontrib>REBOLINI, DANIELA</creatorcontrib><title>A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL</title><description>The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB0VAjwcAzydXR2DQ3xdHb0UXD29w3wD_YM8fT3A7L9Qhw9_Tz93BWcQl1cg_39PF1cFRz9XBTc_IN8_UNcg_x9eBhY0xJzilN5oTQ3g4Kba4izh25qQX58anFBYnJqXmpJvGuAkaWFsZmJmaOhMRFKAJ55Ktw</recordid><startdate>20160217</startdate><enddate>20160217</enddate><creator>CASTEGINI, FRANCO</creator><creator>FAIELLA, GIANLUIGI</creator><creator>CAPONETTI, GIOVANNI</creator><creator>MAGGI, LORETTA</creator><creator>SARDINA, MARCO</creator><creator>REBOLINI, DANIELA</creator><scope>EVB</scope></search><sort><creationdate>20160217</creationdate><title>A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL</title><author>CASTEGINI, FRANCO ; FAIELLA, GIANLUIGI ; CAPONETTI, GIOVANNI ; MAGGI, LORETTA ; SARDINA, MARCO ; REBOLINI, DANIELA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2983646A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2016</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>CASTEGINI, FRANCO</creatorcontrib><creatorcontrib>FAIELLA, GIANLUIGI</creatorcontrib><creatorcontrib>CAPONETTI, GIOVANNI</creatorcontrib><creatorcontrib>MAGGI, LORETTA</creatorcontrib><creatorcontrib>SARDINA, MARCO</creatorcontrib><creatorcontrib>REBOLINI, DANIELA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CASTEGINI, FRANCO</au><au>FAIELLA, GIANLUIGI</au><au>CAPONETTI, GIOVANNI</au><au>MAGGI, LORETTA</au><au>SARDINA, MARCO</au><au>REBOLINI, DANIELA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL</title><date>2016-02-17</date><risdate>2016</risdate><abstract>The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to an inhalable pharmaceutical composition comprising a first powder consisting of budesonide, or one of its pharmaceutically allowable salts, in a quantity greater than 5% w/w of said first powder, leucine in a quantity in the range of 5 to 70% w/w of said first powder, and lactose in a quantity in the range of 20 to 90% w/w of said first powder; a second powder consisting of formoterol, or one of its pharmaceutically allowable salts, in a quantity greater than 1% w/w of said second powder, leucine in a quantity in the range of 5 to 70% w/w of said second powder, and lactose in a quantity in the range of 20 to 90% w/w of said second powder; and a third powder consisting of leucine in a quantity in the range of 5 to 70% w/w of said third powder, and lactose in a quantity in the range of 20 to 90% w/w of said third powder. Said composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 90%.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP2983646A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title A PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T09%3A23%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CASTEGINI,%20FRANCO&rft.date=2016-02-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2983646A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true